Absorption was rapid after oral administration, and the mean maximum observed plasma concentration (Cmax) was reached at a median time of 2 hours after administration. The absolute bioavailability after oral administration has not been determined. The absorption rate and degree of tadalafil are not affected by food, so this product may be taken with or without food. The timing of administration (morning or evening) had no clinically significant effect on absorptance or extent, and the mean volume of distribution was about 63 liters, indicating that tadalala was not distributed into tissues. At treatment concentration, 94% of tadalafil in plasma is bound to protein. Protein binding was not affected by renal impairment. In healthy subjects, the mean oral clearance rate of tadalafil was 2.5L/hr with a mean half-life of 17.5 h. Tadalafil is excreted primarily as inactive metabolites, mainly from the stool (approx. 61% of the dose) and to a lesser extent from the urine (approx. 36% of the dose).
Erectile dysfunction and pulmonary hypertension.
The recommended dose of this product is 10mg and should be taken before sexual activity without being affected by eating. If 10mg is not effective, 20mg can be taken at least 30 minutes before sex.
The maximum dose frequency is once a day.
Eyelid swelling, or what is described as eye pain and conjunctival congestion, is a very rare side effect. Reports indicate that side effects caused by tadalafil are brief, mild, or moderate. These side effects are data that only apply to patients under the age of 75.
Clinical studies have shown that tadalafil can enhance the antihypertensive effect of nitrate drugs. This is thought to be the result of a combination of nitrates and tadalafil acting on the nitric oxide/cGMP pathway. Therefore, patients who are taking nitrates in any form should not take this product.
Having sex poses potential heart risks for people with heart disease. Therefore, erectile dysfunction drugs, including tadalafil, should not be used to advise patients with heart disease who are not sexually active. For patients who already have heart disease, doctors should consider the potential heart risks of sex. The clinical trials that have been conducted do not include patients with the following cardiovascular diseases, so tadalafil is prohibited in these populations:
● Patients who have had myocardial infarction within the last 90 days
● Patients with unstable angina or who have experienced angina during sexual intercourse
● Patients with heart failure who have met the New York Heart Association's diagnostic criteria of Grade 2 or higher in the past 6 months
● Refractory arrhythmia, hypotension (< 90/50mmHg), or refractory hypertension
● Patients who have had a stroke in the last 6 months
● This product should not be taken by persons known to be allergic to tadalafil or its prescribed ingredients